quarterly out , page-35

Spicer69 - Denis said in that BRR that commercial quantities have already been produced, so the critical question you are asking is:

• How many courses have been sold to date?

The other questions are interesting enough, but that one cuts to the core of the issue.

You can ignore the different views about what clinical data may or may not be available, and what that data really means, i.e. whether it can improve the condition of aids, alzheimer's, liver disease sufferers and so on, trying to construct reasons why more capital raising over a couple of years is necessary, the dilution and the significant negative adjustments to the balance sheet of the Siberian company after they bought it, if:

a) meaningful sales quantity is confirmed; and

b) payment for the sales appears in the books.

It is hard to fathom how holders sustain their optimism in the absence of these two critical elements.

The only way must be through having a very high level of confidence that they will occur.

How the unfolding of events so far could have encouraged the forming of even a modest level of confidence completely escapes me.

Nonetheless, good luck. If it works out for holders and they make a great fortune that would be terrific, but I cannot see any reason to believe that is the most likely outcome.